BCL6 is a transcriptional regulator gene which codes for a 706-amino-acid nuclear zinc finger protein. Antibodies to this protein stain the germinal center cells (benign and malignant) in lymphoid follicles, and interfollicular malignant cells in follicular lymphoma, diffuse large B-cell lymphomas, and Burkitt lymphoma, as well as the majority of tumor cells in nodular lymphocyte predominant Hodgkin lymphoma. Anti-BCL6 rarely stains mantle cell lymphoma and MALT lymphoma. BCL6 expression is seen in approximately 68% of ALK+ anaplastic large cell lymphomas (ALCL) and 28% of ALK- ALCL, NK/T-cell lymphoma (27%), peripheral T-cell lymphoma, NOS (8.%), and T-lymphoblastic lymphoma (9.%). BCL6 expression can also be observed in angioimmunoblastic T-cell lymphoma (66%-96%).
BCL6 is a transcriptional regulator gene which codes for a 706-amino-acid nuclear zinc finger protein. Antibodies to this protein stain the germinal center cells (benign and malignant) in lymphoid follicles, and interfollicular malignant cells in follicular lymphoma, diffuse large B-cell lymphomas, and Burkitt lymphoma, as well as the majority of tumor cells in nodular lymphocyte predominant Hodgkin lymphoma. Anti-BCL6 rarely stains mantle cell lymphoma and MALT lymphoma. BCL6 expression is seen in approximately 68% of ALK+ anaplastic large cell lymphomas (ALCL) and 28% of ALK- ALCL, NK/T-cell lymphoma (27%), peripheral T-cell lymphoma, NOS (8.%), and T-lymphoblastic lymphoma (9.%). BCL6 expression can also be observed in angioimmunoblastic T-cell lymphoma (66%-96%).
http://www.cellmarque.com/Cell Marque
BCL6 is a transcriptional regulator gene which codes for a 706-amino-acid nuclear zinc finger protein. Antibodies to this protein stain the germinal center cells (benign and malignant) in lymphoid follicles, and interfollicular malignant cells in follicular lymphoma, diffuse large B-cell lymphomas, and Burkitt lymphoma, as well as the majority of tumor cells in nodular lymphocyte predominant Hodgkin lymphoma. Anti-BCL6 rarely stains mantle cell lymphoma and MALT lymphoma. BCL6 expression is seen in approximately 68% of ALK+ anaplastic large cell lymphomas (ALCL) and 28% of ALK- ALCL, NK/T-cell lymphoma (27%), peripheral T-cell lymphoma, NOS (8.%), and T-lymphoblastic lymphoma (9.%). BCL6 expression can also be observed in angioimmunoblastic T-cell lymphoma (66%-96%).
